Pharma Pulse 8/23/24: Pfizer/BioNTech FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine, Hidden Obstacles in the Script-to-Therapy Journey & more

Overcoming Hidden Obstacles in the Script-to-Therapy Journey

By integrating support directly into existing workflows and focusing on solutions that eliminate "shoulder time," manufacturers can significantly reduce delays and improve patient outcomes.

Pharmacists Can Educate Patients on Sexually Transmitted Infections

Recognizing early signs and seeking medical care is essential for effective treatment and preventing long-term health complications.

How a Law That Shields Big Tech Is Now Being Used Against It

A Massachusetts professor has filed a lawsuit against Meta using a novel interpretation of Section 230, a law known primarily for shielding social media companies from liability.

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies’ Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine. This season’s vaccine is for use as a single dose for most individuals 5 years of age and older. Individuals 5 years of age and older with certain kinds of immunocompromise previously vaccinated with Pfizer and BioNTech COVID-19 vaccines or children under the age of 5 who have not already completed a three-dose series with previous formulas of a COVID-19 vaccine may be eligible to receive additional doses.

PAN Foundation on LinkedIn

In just a few weeks, open enrollment begins for the more than 63 million people enrolled in Medicare programs in the U.S. During this time, many will evaluate and select a Part D plan that best meets their health needs.

In a recent article for Pharmaceutical Commerce Magazine, PAN Foundation Chief Mission Officer Amy Niles, outlined the two important changes coming to Medicare Part D on January 1, 2025—the Medicare Part D cap and the Medicare Prescription Payment Plan.

To learn more about these changes, read the full article here: https://ow.ly/i7Qe50SZJay

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs